A Human Stem Cell-Derived Brain-Liver Chip for Assessing Blood-Brain-Barrier Permeation of Pharmaceutical Drugs

Cells. 2022 Oct 19;11(20):3295. doi: 10.3390/cells11203295.

Abstract

Significant advancements in the field of preclinical in vitro blood-brain barrier (BBB) models have been achieved in recent years, by developing monolayer-based culture systems towards complex multi-cellular assays. The coupling of those models with other relevant organoid systems to integrate the investigation of blood-brain barrier permeation in the larger picture of drug distribution and metabolization is still missing. Here, we report for the first time the combination of a human induced pluripotent stem cell (hiPSC)-derived blood-brain barrier model with a cortical brain and a liver spheroid model from the same donor in a closed microfluidic system (MPS). The two model compounds atenolol and propranolol were used to measure permeation at the blood-brain barrier and to assess metabolization. Both substances showed an in vivo-like permeation behavior and were metabolized in vitro. Therefore, the novel multi-organ system enabled not only the measurement of parent compound concentrations but also of metabolite distribution at the blood-brain barrier.

Keywords: blood-brain barrier (BBB) model; brain–liver chip; human induced pluripotent stem cells (hiPSCs); microphysiological systems (MPS); multi-organ chip.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Atenolol / metabolism
  • Blood-Brain Barrier* / metabolism
  • Brain
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Liver
  • Pharmaceutical Preparations* / metabolism
  • Propranolol / metabolism

Substances

  • Atenolol
  • Pharmaceutical Preparations
  • Propranolol

Grants and funding

This work was supported by public funding from the German Ministry for Education and Research BMBF (HiPSTAR, funding code: 01EK1608E).